Continuity BiosciencesEnabling Breakthrough Therapieswith Novel Delivery Technologies Convergence of biopharmaceuticals, drug delivery approaches, and medical technologies is realizing therapies that are not possible through any of these fields individually – products that benefit from this convergence are called combination products.Robert Whitehead, Alessandro Grattoni and Ramakrishna Venugopalan founded Continuity Biosciences in 2024 with the aspiration of
Location: United States
Mentions in press and media 8
| Date | Title | Description |
| 30.07.2026 | Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors | Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vic... |
| 20.05.2026 | Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer | Study now open for enrollment at leading academic medical centers CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, ... |
| 24.03.2026 | Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study | Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading globa... |
| 04.06.2025 | Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer | BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneeri... |
| 30.04.2025 | Continuity Biosciences backs Joseph DeSimone PinPrint’s unique 3D printed microneedle tech | US-based biotechnology company Continuity Biosciences has invested in 3D printed microneedle technology specialist PinPrint to expand its focus from therapeutic delivery into aesthetic and cosmetic applications. Designed to deliver vaccines... |
| 29.04.2025 | Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery | BRADENTON, Fla., April 29, 2025 /PRNewswire/ -- Continuity Biosciences, LLC has made a strategic investment in PinPrint, Inc., a pioneering company in high-resolution 3D-printed microneedle technology. The investment expands Continuity's fo... |
| 13.11.2024 | Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies | BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug deliv... |
| - | Continuity Biosciences | - |